Development of non-invasive methods of genetic diagnosis and cancer prevention. (Q107971): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Created claim: summary (P836): The project is an attempt to address the problem of cancer diagnosis in a comprehensive way. The current state of medical knowledge makes it possible to treat an increasing number of diseases, but it is often too late to detect them. The development of diagnostic methods makes it possible to use non-invasive methods that use non-invasive methods based on the free, out-of-the-cell DNA in recent years, present in the plasma of every human being, a...) |
||
| Property / summary | |||
The project is an attempt to address the problem of cancer diagnosis in a comprehensive way. The current state of medical knowledge makes it possible to treat an increasing number of diseases, but it is often too late to detect them. The development of diagnostic methods makes it possible to use non-invasive methods that use non-invasive methods based on the free, out-of-the-cell DNA in recent years, present in the plasma of every human being, and in increased quantities and abnormal structures in cancer patients. In addition to the analysis of mutations which characterise the cancer tissue, it will be explored to analyse changes in the number of copies and abdictions of structural bias on the basis of a statistical analysis of the disturbance of the patient’s genome coverage. As the existing studies show, the evolution of the number of copies/abberations in the DNA cycle DNA sequencing data can indicate the presence of cancer, the type and the state of the cancer. With its research team, Genomed S.A. plans to develop an innovative method for the genetic profiling of cancer, a non-invasive diagnosis of cancer, to monitor the course of illness and treatment. The result will be an optimised cancer diagnosis for the Polish population, with the possibility to make data available through a web-based platform for telemedicine applications. In the course of research on the basis of data from the sequencing of free, cancer DNA, a method will be developed to detect mutations specific to cancer in cancer patients and structural changes in the cancer process. The data thus obtained will allow individual treatments (including patient inclusion in the clinical trial) and monitoring of the course of treatment without requiring costly and painful biopsy. (English) | |||
| Property / summary: The project is an attempt to address the problem of cancer diagnosis in a comprehensive way. The current state of medical knowledge makes it possible to treat an increasing number of diseases, but it is often too late to detect them. The development of diagnostic methods makes it possible to use non-invasive methods that use non-invasive methods based on the free, out-of-the-cell DNA in recent years, present in the plasma of every human being, and in increased quantities and abnormal structures in cancer patients. In addition to the analysis of mutations which characterise the cancer tissue, it will be explored to analyse changes in the number of copies and abdictions of structural bias on the basis of a statistical analysis of the disturbance of the patient’s genome coverage. As the existing studies show, the evolution of the number of copies/abberations in the DNA cycle DNA sequencing data can indicate the presence of cancer, the type and the state of the cancer. With its research team, Genomed S.A. plans to develop an innovative method for the genetic profiling of cancer, a non-invasive diagnosis of cancer, to monitor the course of illness and treatment. The result will be an optimised cancer diagnosis for the Polish population, with the possibility to make data available through a web-based platform for telemedicine applications. In the course of research on the basis of data from the sequencing of free, cancer DNA, a method will be developed to detect mutations specific to cancer in cancer patients and structural changes in the cancer process. The data thus obtained will allow individual treatments (including patient inclusion in the clinical trial) and monitoring of the course of treatment without requiring costly and painful biopsy. (English) / rank | |||
Normal rank | |||
Revision as of 09:50, 9 March 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of non-invasive methods of genetic diagnosis and cancer prevention. |
Project in Poland financed by DG Regio |
Statements
2,071,253.46 zloty
0 references
3,206,751.46 zloty
0 references
67.18 percent
0 references
1 October 2016
0 references
31 December 2018
0 references
GENOMED SPÓŁKA AKCYJNA
0 references
52°14'1.3"N, 21°4'17.0"E
0 references
Prezentowany projekt stanowi próbę kompleksowego podejścia do problemu diagnostyki chorób nowotworowych. Obecny stan wiedzy medycznej pozwala leczyć coraz większą liczbę chorób, jednakże często ich wykrycie następuje zdecydowanie za późno. Rozwój metod diagnostycznych umożliwia zastosowanie wysokoprzepustowych technologii, wykorzystujących metody nieinwazyjne, oparte na odkrytym w ostatnich latach wolnym, pozakomórkowym DNA, obecnym w osoczu krwi każdego człowieka, a w zwiększonych ilościach i anormalnej strukturze u pacjentów onkologicznych. Oprócz analizy mutacji, charakteryzujących tkankę nowotworową, zostanie zbadana możliwość analizy zmian liczby kopii i abberacji strukturalnych na podstawie statystycznej analizy zaburzeń w pokryciu genomu pacjenta. Jak pokazują dotychczasowe badania, zmiany liczby kopii/ abberacje obecne w danych z sekwencjonowania wolnego nowotworowego DNA mogą świadczyć o występowaniu nowotworu, jego typie i stanie zaawansowania. Genomed S.A. ze swym zespołem badawczym wychodzi naprzeciwko oczekiwaniom rynku i w ramach projektu planuje opracowanie innowacyjnej metody profilowania genetycznego nowotworów - nieinwazyjnej diagnostyki chorób nowotworowych, umożliwiającej monitorowanie przebiegu choroby i leczenia. Efektem prac będzie zoptymalizowana kosztowo diagnostyka chorób nowotworowych dla populacji polskiej, z możliwością udostępnienia danych poprzez platformę internetową do zastosowań w telemedycynie. W toku prac badawczych na podstawie danych z sekwencjonowania wolnego, nowotworowego DNA pacjentów zostanie opracowana metoda umożliwiająca wykrycie mutacji specyficznych dla tkanki nowotworowej pacjentów onkologicznych oraz charakterystycznych dla procesów nowotworowych zmian strukturalnych. Uzyskane w ten sposób dane umożliwią dobranie indywidualnej terapii (czy też włączenie pacjenta w badania kliniczne) i monitorowanie przebiegu leczenia bez konieczności wykonywania kosztownych i bolesnych biopsji. (Polish)
0 references
The project is an attempt to address the problem of cancer diagnosis in a comprehensive way. The current state of medical knowledge makes it possible to treat an increasing number of diseases, but it is often too late to detect them. The development of diagnostic methods makes it possible to use non-invasive methods that use non-invasive methods based on the free, out-of-the-cell DNA in recent years, present in the plasma of every human being, and in increased quantities and abnormal structures in cancer patients. In addition to the analysis of mutations which characterise the cancer tissue, it will be explored to analyse changes in the number of copies and abdictions of structural bias on the basis of a statistical analysis of the disturbance of the patient’s genome coverage. As the existing studies show, the evolution of the number of copies/abberations in the DNA cycle DNA sequencing data can indicate the presence of cancer, the type and the state of the cancer. With its research team, Genomed S.A. plans to develop an innovative method for the genetic profiling of cancer, a non-invasive diagnosis of cancer, to monitor the course of illness and treatment. The result will be an optimised cancer diagnosis for the Polish population, with the possibility to make data available through a web-based platform for telemedicine applications. In the course of research on the basis of data from the sequencing of free, cancer DNA, a method will be developed to detect mutations specific to cancer in cancer patients and structural changes in the cancer process. The data thus obtained will allow individual treatments (including patient inclusion in the clinical trial) and monitoring of the course of treatment without requiring costly and painful biopsy. (English)
0 references
Identifiers
RPMA.01.02.00-14-6209/16
0 references